

Drugs for Vulvovaginal Candidiasis-Global Market Status and Trend Report 2013-2023

https://marketpublishers.com/r/D840185433AMEN.html

Date: May 2018 Pages: 160 Price: US\$ 2,480.00 (Single User License) ID: D840185433AMEN

Abstracts

Report Summary

Drugs for Vulvovaginal Candidiasis-Global Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Drugs for Vulvovaginal Candidiasis industry, standing on the readers? perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Regional Market Size of Drugs for Vulvovaginal Candidiasis 2013-2017, and development forecast 2018-2023

Main manufacturers/suppliers of Drugs for Vulvovaginal Candidiasis worldwide, with company and product introduction, position in the Drugs for Vulvovaginal Candidiasis market

Market status and development trend of Drugs for Vulvovaginal Candidiasis by types and applications

Cost and profit status of Drugs for Vulvovaginal Candidiasis, and marketing status Market growth drivers and challenges

The report segments the global Drugs for Vulvovaginal Candidiasis market as:

Global Drugs for Vulvovaginal Candidiasis Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

North America



Europe

China Japan Rest APAC Latin America

Global Drugs for Vulvovaginal Candidiasis Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Miconazole Clotrimazole Fluconazole Ketoconazole Others

Global Drugs for Vulvovaginal Candidiasis Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Premarital women Married women

Global Drugs for Vulvovaginal Candidiasis Market: Manufacturers Segment Analysis (Company and Product introduction, Drugs for Vulvovaginal Candidiasis Sales Volume, Revenue, Price and Gross Margin):

Bayer Janssen Viamet Pharmaceuticals Actavis Tianjin Kingyork Group Tianjin Pacific Pharmaceutical Cisen Pharmaceutical

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.



Contents

CHAPTER 1 OVERVIEW OF DRUGS FOR VULVOVAGINAL CANDIDIASIS

- 1.1 Definition of Drugs for Vulvovaginal Candidiasis in This Report
- 1.2 Commercial Types of Drugs for Vulvovaginal Candidiasis
- 1.2.1 Miconazole
- 1.2.2 Clotrimazole
- 1.2.3 Fluconazole
- 1.2.4 Ketoconazole
- 1.2.5 Others
- 1.3 Downstream Application of Drugs for Vulvovaginal Candidiasis
- 1.3.1 Premarital women
- 1.3.2 Married women
- 1.4 Development History of Drugs for Vulvovaginal Candidiasis
- 1.5 Market Status and Trend of Drugs for Vulvovaginal Candidiasis 2013-2023
 - 1.5.1 Global Drugs for Vulvovaginal Candidiasis Market Status and Trend 2013-2023

1.5.2 Regional Drugs for Vulvovaginal Candidiasis Market Status and Trend 2013-2023

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Drugs for Vulvovaginal Candidiasis 2013-2017
- 2.2 Sales Market of Drugs for Vulvovaginal Candidiasis by Regions
- 2.2.1 Sales Volume of Drugs for Vulvovaginal Candidiasis by Regions
- 2.2.2 Sales Value of Drugs for Vulvovaginal Candidiasis by Regions
- 2.3 Production Market of Drugs for Vulvovaginal Candidiasis by Regions
- 2.4 Global Market Forecast of Drugs for Vulvovaginal Candidiasis 2018-2023
- 2.4.1 Global Market Forecast of Drugs for Vulvovaginal Candidiasis 2018-2023
- 2.4.2 Market Forecast of Drugs for Vulvovaginal Candidiasis by Regions 2018-2023

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Drugs for Vulvovaginal Candidiasis by Types
- 3.2 Sales Value of Drugs for Vulvovaginal Candidiasis by Types
- 3.3 Market Forecast of Drugs for Vulvovaginal Candidiasis by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY



4.1 Global Sales Volume of Drugs for Vulvovaginal Candidiasis by Downstream Industry4.2 Global Market Forecast of Drugs for Vulvovaginal Candidiasis by DownstreamIndustry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

5.1 North America Drugs for Vulvovaginal Candidiasis Market Status by Countries5.1.1 North America Drugs for Vulvovaginal Candidiasis Sales by Countries(2013-2017)

5.1.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2017)

5.1.3 United States Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

5.1.4 Canada Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

5.1.5 Mexico Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

5.2 North America Drugs for Vulvovaginal Candidiasis Market Status by Manufacturers 5.3 North America Drugs for Vulvovaginal Candidiasis Market Status by Type (2013-2017)

5.3.1 North America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2017)

5.3.2 North America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2017)

5.4 North America Drugs for Vulvovaginal Candidiasis Market Status by Downstream Industry (2013-2017)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Drugs for Vulvovaginal Candidiasis Market Status by Countries
 - 6.1.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2017)
 - 6.1.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2017)
 - 6.1.3 Germany Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
 - 6.1.4 UK Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
 - 6.1.5 France Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
 - 6.1.6 Italy Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
 - 6.1.7 Russia Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
 - 6.1.8 Spain Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
 - 6.1.9 Benelux Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)
- 6.2 Europe Drugs for Vulvovaginal Candidiasis Market Status by Manufacturers



6.3 Europe Drugs for Vulvovaginal Candidiasis Market Status by Type (2013-2017)
6.3.1 Europe Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2017)
6.3.2 Europe Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2017)
6.4 Europe Drugs for Vulvovaginal Candidiasis Market Status by Downstream Industry (2013-2017)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

7.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Status by Countries
7.1.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2017)
7.1.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Countries
(2013-2017)

7.1.3 China Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

7.1.4 Japan Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

7.1.5 India Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

7.1.6 Southeast Asia Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

7.1.7 Australia Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

7.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Status by Manufacturers

7.3 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Status by Type (2013-2017)

7.3.1 Asia Pacific Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2017)

7.3.2 Asia Pacific Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2017)7.4 Asia Pacific Drugs for Vulvovaginal Candidiasis Market Status by Downstream Industry (2013-2017)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

8.1 Latin America Drugs for Vulvovaginal Candidiasis Market Status by Countries8.1.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Countries(2013-2017)

8.1.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2017)

8.1.3 Brazil Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

8.1.4 Argentina Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

8.1.5 Colombia Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

8.2 Latin America Drugs for Vulvovaginal Candidiasis Market Status by Manufacturers8.3 Latin America Drugs for Vulvovaginal Candidiasis Market Status by Type(2013-2017)



8.3.1 Latin America Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2017)
8.3.2 Latin America Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2017)
8.4 Latin America Drugs for Vulvovaginal Candidiasis Market Status by Downstream
Industry (2013-2017)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

9.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Status by Countries

9.1.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Countries (2013-2017)

9.1.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Countries (2013-2017)

9.1.3 Middle East Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

9.1.4 Africa Drugs for Vulvovaginal Candidiasis Market Status (2013-2017)

9.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Status by Manufacturers

9.3 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Status by Type (2013-2017)

9.3.1 Middle East and Africa Drugs for Vulvovaginal Candidiasis Sales by Type (2013-2017)

9.3.2 Middle East and Africa Drugs for Vulvovaginal Candidiasis Revenue by Type (2013-2017)

9.4 Middle East and Africa Drugs for Vulvovaginal Candidiasis Market Status by Downstream Industry (2013-2017)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF DRUGS FOR VULVOVAGINAL CANDIDIASIS

10.1 Global Economy Situation and Trend Overview

10.2 Drugs for Vulvovaginal Candidiasis Downstream Industry Situation and Trend Overview

CHAPTER 11 DRUGS FOR VULVOVAGINAL CANDIDIASIS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of Drugs for Vulvovaginal Candidiasis by Major Manufacturers 11.2 Production Value of Drugs for Vulvovaginal Candidiasis by Major Manufacturers



11.3 Basic Information of Drugs for Vulvovaginal Candidiasis by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Drugs for Vulvovaginal Candidiasis Major Manufacturer

11.3.2 Employees and Revenue Level of Drugs for Vulvovaginal Candidiasis Major Manufacturer

- 11.4 Market Competition News and Trend
- 11.4.1 Merger, Consolidation or Acquisition News
- 11.4.2 Investment or Disinvestment News
- 11.4.3 New Product Development and Launch

CHAPTER 12 DRUGS FOR VULVOVAGINAL CANDIDIASIS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 Bayer

- 12.1.1 Company profile
- 12.1.2 Representative Drugs for Vulvovaginal Candidiasis Product
- 12.1.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of Bayer
- 12.2 Janssen
 - 12.2.1 Company profile
- 12.2.2 Representative Drugs for Vulvovaginal Candidiasis Product
- 12.2.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of Janssen

12.3 Viamet Pharmaceuticals

- 12.3.1 Company profile
- 12.3.2 Representative Drugs for Vulvovaginal Candidiasis Product
- 12.3.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of Viamet Pharmaceuticals
- 12.4 Actavis
- 12.4.1 Company profile
- 12.4.2 Representative Drugs for Vulvovaginal Candidiasis Product
- 12.4.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of Actavis
- 12.5 Tianjin Kingyork Group
 - 12.5.1 Company profile
 - 12.5.2 Representative Drugs for Vulvovaginal Candidiasis Product
- 12.5.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of

Tianjin Kingyork Group

12.6 Tianjin Pacific Pharmaceutical



12.6.1 Company profile

12.6.2 Representative Drugs for Vulvovaginal Candidiasis Product

12.6.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of Tianjin Pacific Pharmaceutical

12.7 Cisen Pharmaceutical

12.7.1 Company profile

12.7.2 Representative Drugs for Vulvovaginal Candidiasis Product

12.7.3 Drugs for Vulvovaginal Candidiasis Sales, Revenue, Price and Gross Margin of Cisen Pharmaceutical

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF DRUGS FOR VULVOVAGINAL CANDIDIASIS

- 13.1 Industry Chain of Drugs for Vulvovaginal Candidiasis
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF DRUGS FOR VULVOVAGINAL CANDIDIASIS

- 14.1 Cost Structure Analysis of Drugs for Vulvovaginal Candidiasis
- 14.2 Raw Materials Cost Analysis of Drugs for Vulvovaginal Candidiasis
- 14.3 Labor Cost Analysis of Drugs for Vulvovaginal Candidiasis
- 14.4 Manufacturing Expenses Analysis of Drugs for Vulvovaginal Candidiasis

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
- 16.1.1 Research Programs/Design
- 16.1.2 Market Size Estimation
- 16.1.3 Market Breakdown and Data Triangulation

16.2 Data Source

- 16.2.1 Secondary Sources
- 16.2.2 Primary Sources
- 16.3 Reference



I would like to order

Product name: Drugs for Vulvovaginal Candidiasis-Global Market Status and Trend Report 2013-2023 Product link: <u>https://marketpublishers.com/r/D840185433AMEN.html</u>

Price: US\$ 2,480.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/D840185433AMEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970